Endoscopy Unit, Hospital Israelita Albert Einstein, São Paulo SP, Brazil.
Gastrointest Endosc. 2018 Jan;87(1):131.e1-131.e13. doi: 10.1016/j.gie.2017.04.013. Epub 2017 Apr 25.
Biliary anastomotic stricture occurs in 15% to 20% of patients after deceased orthotopic liver transplantation (OLT). It is usually treated endoscopically with multiple plastic stents (MPSs), although the use of fully covered self-expandable metal stents (cSEMSs) is emerging. This study aims to compare the efficacy and safety of cSEMSs versus MPSs in these patients.
A single-center, open-label, randomized clinical trial was performed. Patients were randomized to single cSEMSs for 6 months or to MPS placement, exchanged every 3 months over 1 year. The primary outcome was stricture resolution. Crossover therapy was considered for failure or recurrence. Secondary outcomes were sustained improvement, morbidity, and mortality.
Between October 2009 and January 2014, 162 patients with post-OLT biliary adverse events were assessed for eligibility. Sixty-four were prospectively randomized (1:1) to cSEMSs or MPSs. Baseline characteristics were comparable. Technical success was 100%. Median follow-up was 36.4 and 32.9 months for the cSEMS and MPS groups, stricture resolution at last stent removal was achieved in 83.3% and 96.5% (P = .19), and stricture recurrence was observed in 32% and 0%, respectively (P < .01). Adverse events occurred in 23.3% and 6.4% of ERCPs in the cSEMS and MPS groups, respectively (P < .01), with 13.3% of acute pancreatitis in the cSEMS group and 2.1% in the MPS group (P < .01).
cSEMSs were comparable with MPSs regarding post-OLT biliary anastomotic stricture resolution. cSEMSs allowed fewer procedures and had a positive effect on cost. Duration of treatment with cSEMSs should be further investigated. Sphincterotomy should be considered for all patients. (Clinical trial registration number: NCT 01148199.).
在接受尸体原位肝移植(OLT)后的 15%至 20%的患者中会发生胆肠吻合口狭窄。通常通过多次放置塑料支架(MPSs)进行内镜治疗,尽管正在出现全覆膜自膨式金属支架(cSEMSs)的应用。本研究旨在比较这些患者中 cSEMSs 与 MPSs 的疗效和安全性。
进行了一项单中心、开放标签、随机临床试验。将患者随机分为接受单根 cSEMSs 治疗 6 个月或接受 MPS 放置治疗,每 3 个月更换一次,持续 1 年。主要结局是狭窄缓解。对于失败或复发,考虑交叉治疗。次要结局为持续改善、发病率和死亡率。
在 2009 年 10 月至 2014 年 1 月期间,评估了 162 例 OLT 后胆系不良事件患者的纳入资格。64 例患者前瞻性随机(1:1)分为 cSEMSs 或 MPSs 组。基线特征具有可比性。技术成功率为 100%。cSEMS 组和 MPS 组的中位随访时间分别为 36.4 和 32.9 个月,最后一次支架取出时狭窄缓解率分别为 83.3%和 96.5%(P=0.19),狭窄复发率分别为 32%和 0%(P<0.01)。cSEMS 组和 MPS 组的 ERCP 相关不良事件发生率分别为 23.3%和 6.4%(P<0.01),cSEMS 组发生急性胰腺炎的比例为 13.3%,MPS 组为 2.1%(P<0.01)。
cSEMSs 在治疗 OLT 后胆肠吻合口狭窄方面与 MPSs 疗效相当。cSEMSs 减少了治疗次数,对成本有积极影响。cSEMSs 的治疗持续时间需要进一步研究。应考虑对所有患者进行括约肌切开术。(临床试验注册号:NCT 01148199.)。